Cargando…

A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells

Treatment of HER2+ breast cancer with trastuzumab is effective and combination anti-HER2 therapies have demonstrated benefit over monotherapy in the neoadjuvant and metastatic settings. This study investigated the therapeutic potential of targeting the BAG-1 protein co-chaperone in trastuzumab-respo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Papadakis, Emmanouil, Robson, Natalia, Yeomans, Alison, Bailey, Sarah, Laversin, Stephanie, Beers, Stephen, Sayan, A. Emre, Ashton-Key, Margaret, Schwaiger, Stefan, Stuppner, Hermann, Troppmair, Jakob, Packham, Graham, Cutress, Ramsey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951334/ https://www.ncbi.nlm.nih.gov/pubmed/26958811 http://dx.doi.org/10.18632/oncotarget.7944

Ejemplares similares

The Bag-1 inhibitor, Thio-2, reverses an atypical 3D morphology driven by Bag-1L overexpression in a MCF-10A model of ductal carcinoma in situ
por: Papadakis, E S, et al.
Publicado: (2016)

Prognostic significance of crown-like structures to trastuzumab response in patients with primary invasive HER2 + breast carcinoma
por: Birts, Charles N., et al.
Publicado: (2022)

BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses
por: Papadakis, E S, et al.
Publicado: (2017)

Reply to ‘Comment on ‘BAG-1 as a biomarker in early breast cancer prognosis: a systematic review with meta-analyses’’
por: Papadakis, E. S., et al.
Publicado: (2018)

Regulation of osteoblast development by Bcl-2-associated athanogene-1 (BAG-1)
por: Greenhough, Joanna, et al.
Publicado: (2016)

BAG-1 expression and function in human cancer
por: Cutress, R I, et al.
Publicado: (2002)

Unusual Secondary Metabolites of the Aerial Parts of Dionysia diapensifolia Bioss. (Primulaceae) and Their Anti-Inflammatory Activity
por: Alilou, Mostafa, et al.
Publicado: (2020)

Antiausterity Activity of Secondary Metabolites from the Roots of Ferula hezarlalehzarica against the PANC-1 Human Pancreatic Cancer Cell Line
por: Alilou, Mostafa, et al.
Publicado: (2020)

Labdane-Type Diterpenes from the Aerial Parts of Rydingia persica: Their Absolute Configurations and Protective Effects on LPS-Induced Inflammation in Keratinocytes
por: Alilou, Mostafa, et al.
Publicado: (2020)

Synergistic Effects of Metformin and Trastuzumab on HER2 Positive Gastroesophageal Adenocarcinoma Cells In Vitro and In Vivo
por: Kim, Jin-Soo, et al.
Publicado: (2023)

Annexin A3 is a mammary marker and a potential neoplastic breast cell therapeutic target
por: Zeidan, Bashar, et al.
Publicado: (2015)

Quantitative analysis of anti-inflammatory lignan derivatives in Ratanhiae radix and its tincture by HPLC–PDA and HPLC–MS
por: Baumgartner, Lisa, et al.
Publicado: (2011)

Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells
por: Vanderhoeven, Fiorella, et al.
Publicado: (2018)

The effects of restricted glycolysis on stem-cell like characteristics of breast cancer cells
por: Banerjee, Arindam, et al.
Publicado: (2018)

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
por: Yarlagadda, Bhavya, et al.
Publicado: (2019)

Correction: Synergistic antitumor activity by combining trastuzumab with retinoic acid in HER2 positive human breast cancer cells
por: Vanderhoeven, Fiorella, et al.
Publicado: (2023)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Lignan formation in hairy root cultures of Edelweiss (Leontopodium nivale ssp. alpinum (Cass.) Greuter)
por: Wawrosch, Christoph, et al.
Publicado: (2014)

Tyrosinase Inhibitors from the Aerial Parts of Wulfenia carinthiaca jacq.
por: Mutschlechner, Benjamin, et al.
Publicado: (2018)

Determination of Phytochemical Contents in Extracts from Different Growth Stages of Oroxylum indicum Fruits Using HPLC-DAD and QAMS Methods
por: Rojsanga, Piyanuch, et al.
Publicado: (2023)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

A novel nanobody-based HER2-targeting antibody exhibits potent synergistic antitumor efficacy in trastuzumab-resistant cancer cells
por: Liu, Xinlin, et al.
Publicado: (2023)

Obesity Is Associated with Immunometabolic Changes in Adipose Tissue That May Drive Treatment Resistance in Breast Cancer: Immune-Metabolic Reprogramming and Novel Therapeutic Strategies
por: Savva, Constantinos, et al.
Publicado: (2023)

Anti-Inflammatory and Anti-Oxidant Potential of the Root Extract and Constituents of Doronicum austriacum
por: Marzocco, Stefania, et al.
Publicado: (2017)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

The BAG-1 cochaperone is a negative regulator of p73-dependent transcription
por: Wang, X-H, et al.
Publicado: (2009)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

Synergistic antitumor efficacy against the EGFRvIII(+)HER2(+) breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12
por: Xu, Wen, et al.
Publicado: (2015)

Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
por: Bundred, Nigel, et al.
Publicado: (2022)

Simultaneous Quantitative Analysis of the Major Bioactive Compounds in Gentianae Radix and its Beverages by UHPSFC–DAD
por: Gibitz-Eisath, Nora, et al.
Publicado: (2022)

The D. M. C’s Reply to “One of Her Boys”
por: Packham, Albany
Publicado: (1859)

Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
por: Upton, Rosalynd, et al.
Publicado: (2021)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
por: Maadi, Hamid, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_elelhvj8slb81rbmj2nata4ba3